1.Acute Upper Extremity Ischemia Caused by a Tumor Embolism
Yoshiyuki Yamashita ; Sosei Kuma ; Atsushi Guntani ; Ryota Fukunaga ; Jin Okazaki
Japanese Journal of Cardiovascular Surgery 2012;41(6):289-292
A 52-year-old woman had undergone colectomy and adjuvant chemotherapy for stage IV cecal cancer with peritoneal dissemination and multiple metastases to the lung and liver. After two years of follow-up, she suddenly had right upper limb pain and was reffered to our hospital for treatment of acute upper limb ischemia. Enhanced CT revealed obstruction of the right brachial artery and metastatic lung cancer with pulmonary vein invasion. We performed emergency embolectomy with local anesthesia. The patient's perioperative course was uneventful. Pathological findings of the removed embolus revealed that it contained adenocarcinoma cells. We concluded that the embolus had originated from the metastatic lung cancer with pulmonary vein invasion.
2.An Investigation into the Clinical Use of Botulinum Toxin Type A to Treat Post-stroke Hemiplegic Patients with Upper and/or Lower Limb Spasticity
Akio KIMURA ; Masahiro ABO ; Yoshihisa MASAKADO ; Yoshiyuki YAMASHITA ; Toshio MAEDA
The Japanese Journal of Rehabilitation Medicine 2015;52(7):421-430
A multicenter review of the medical records of Japanese post-stroke patients with spastic hemiplegia was conducted to investigate the clinical use of botulinum toxin type A (BoNT/A) by physicians with expertise in the treatment of upper and lower limb spasticity. An analysis of the data from 307 patients treated with BoNT/A during the period January 1, 2012 to November 30, 2013 provided a variety of information on factors relating to BoNT/A injection outcomes, including the total dose of BoNT/A per treatment session, the dose of BoNT/A per muscle, the number of injection sites per muscle, the method used to locate the muscles to be injected, and the dilution of reconstituted BoNT/A. Our analysis indicated that the dose of BoNT/A administered per muscle was usually selected by taking into consideration the severity of spasticity, rather than the patient's body size. Since the technical expertise of experienced clinicians is summarized in this data, it may serve as a useful reference for the use of BoNT/A in routine clinical practice.
3.A Case of Tricuspid Valve Repair with a Flexible Band in a Patient with Situs Inversus Totalis
Masayuki SHIMADA ; Yoshiyuki YAMASHITA ; Masayoshi UMESUE
Japanese Journal of Cardiovascular Surgery 2023;52(6):406-411
Tricuspid annulus has an asymmetric three-dimensional structure with the posteroseptalportion lowest toward the apex from the right atrium and the anteroseptal portion the highest. The tricuspid annulus of a patient with situs inversus has a mirror image of a patient with situs solitus, and the posteroseptal and the anteroseptal portion remains the lowest and the highest toward the apex, respectively, as the situs solitus. Therefore, we assumed that the posteroseptal portion would become higher and the anteroseptal portion would become lower using a conventional three-dimensional rigid ring turned over for tricuspid regurgitation in the situs inversus, and the coaptation of the three leaflets would be poor. In this case, we performed tricuspid annuloplasty using a tricuspid flexible band, mitral valve plasty, left atrial plication, left atrial appendage closure for a situs inversus dextrocardia patient with tricuspid regurgitation, mitral regurgitation, and chronic atrial fibrillation.
4.Utility of Elastography with Endoscopic Ultrasonography Shear-Wave Measurement for Diagnosing Chronic Pancreatitis
Yasunobu YAMASHITA ; Kensuke TANIOKA ; Yuki KAWAJI ; Takashi TAMURA ; Junya NUTA ; Keiichi HATAMARU ; Masahiro ITONAGA ; Takeichi YOSHIDA ; Yoshiyuki IDA ; Takao MAEKITA ; Mikitaka IGUCHI ; Masayuki KITANO
Gut and Liver 2020;14(5):659-664
Background/Aims:
Rosemont classification (RC) with en-doscopic ultrasonography (EUS) is important for diagnosing chronic pancreatitis (CP) but is based only on subjective judgement. EUS shear wave measurement (EUS-SWM) is a precise modality based on objective judgment, but its usefulness has not been extensively studied yet. This study evaluated the utility of EUS-SWM for diagnosing CP and esti-mating CP severity by determining the presence of endocrine dysfunction along with diabetes mellitus (DM).
Methods:
Between June 2018 and December 2018, 52 patients who underwent EUS and EUS-SWM were classified into two groups according to RC: non-CP (indeterminate CP and normal) and CP (consistent and suggestive of CP). The EUSSWM value by shear wave velocity was evaluated with a me-dian value. The EUS-SWM value was compared with RC and the number of EUS features. The diagnostic accuracy and cutoff value of EUS-SWM for CP and DM and its sensitivity and specificity were calculated.
Results:
The EUS-SWM value significantly positively correlated with the RC and the number of EUS features. The EUS-SWM values that were consistent and suggestive of CP were significantly higher than that of normal. The area under the receiver operating characteristic (AUROC) curve for the diagnostic accuracy of EUS-SWM for CP was 0.97. The cutoff value of 2.19 had 100% sensitivity and 94% specificity. For endocrine dysfunction in CP, the AUROC was 0.75. The cutoff value of 2.78 had 70% sensitiv-ity and 56% specificity.
Conclusions
EUS-SWM provides an objective assessment and can be an alternative diagnostic tool for diagnosing CP. EUS-SWM may also be useful for pre-dicting the presence of endocrine dysfunction.